Table 2.
Serum and urinary biochemical parameters of patients with chronic hepatitis B virus infection in use or not of antiretrovirals.
| Variables | Group 1 Without antiretrovirals |
Group 2 Tenofovir |
Group 3 Lamivudine/Entecavir |
p value | Reference values |
|---|---|---|---|---|---|
| n | 27 | 27 | 27 | ||
| DPD (nmol/mmol) | 8.09 ± 2.98 | 9.23 ± 2.4 | 8.29 ± 2.5 | 0.295 | 2.3–7.4 |
| Osteocalcin (ng/ml) | 7.3 ± 3.95a | 10.6 ± 5.67b | 7.50 ± 3.85ab | 0.025 | < 2–21 |
| PTH (pg/ml) | 35.1 ± 16.0ab | 43.2 ± 25.0b | 28.0 ± 9.5a | 0.011 | 10–65 |
| IGF-1 (ng/ml) | 191.5 ± 115.4 | 145.1 ± 69.2 | 137.1 ± 91.9 | 0.236 | 101–267 |
| FGF-23 (pg/ml) | 62.2 ± 24.7 | 54 ± 14.1 | 49.1 ± 19.2 | 0.168 | 23.2–95.4 |
| 25 OH vitamin D (ng/ml) | 27.1 ± 7.1a | 32.8 ± 9.2b | 32.8 ± 7.9b | 0.015 | > 20 |
| Total calcium (mg/dl) | 9.23 ± 0.48 | 9.08 ± 0.42 | 9.17 ± 0.33 | 0.539 | 8.8–11 |
| Phosphorus (mg/dl) | 3.97 ± 0.64 | 3.66 ± 0.52 | 3.64 ± 0.61 | 0.086 | 3–7 |
| Magnesium (mg/dl) | 2.19 ± 0.18 | 2.21 ± 0.19 | 2.23 ± 0.18 | 0.686 | 1.9–2.5 |
| Urinary phosphorus (mg/l) | 538,6 ± 317,9 | 652,6 ± 349,2 | 487,9 ± 273,7 | 0.133 | 400–1300 |
| GOT (U/l) | 24.5 ± 10.3 | 24.0 ± 6.14 | 24.4 ± 9.2 | 0.982 | 5–40 |
| GPT (U/l) | 28.2 ± 18.4 | 27.7 ± 16.0 | 30.1 ± 20.1 | 0.876 | 7–56 |
| Creatinine (mg/dl) | 0.87 ± 0.1 | 0.90 ± 0.2 | 0.96 ± 0.2 | 0.375 | 0.6–1.2 |
| Urea (mg/dl) | 27.8 ± 7.9 | 28.6 ± 6.9 | 30.5 ± 8.0 | 0.413 | 10–40 |
| Albumin (g/dl) | 4.3 ± 0.5 | 4.3 ± 0.3 | 4.5 ± 0.3 | 0.099 | 3.5–4.7 |
ANOVA one way. Values are expressed as mean ± standard deviation. Different letters p ≤ 0.05. DPD, deoxypyridinoline; PTH, parathormone; IGF-1, insulin-like growth factor-1; FGF-23, fibroblast growth factor 23; GOT, glutamic-oxaloacetic transaminase; GPT, glutamic-pyruvic transaminase. FGF-23 n = 16–17 per group.